223 related articles for article (PubMed ID: 21600250)
21. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.
Drummond DC; Noble CO; Guo Z; Hong K; Park JW; Kirpotin DB
Cancer Res; 2006 Mar; 66(6):3271-7. PubMed ID: 16540680
[TBL] [Abstract][Full Text] [Related]
22. Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma.
Nik ME; Malaekeh-Nikouei B; Amin M; Hatamipour M; Teymouri M; Sadeghnia HR; Iranshahi M; Jaafari MR
Sci Rep; 2019 Jul; 9(1):9527. PubMed ID: 31267009
[TBL] [Abstract][Full Text] [Related]
23. Palmitoyl ascorbate and doxorubicin co-encapsulated liposome for synergistic anticancer therapy.
Yang Y; Lu X; Liu Q; Dai Y; Zhu X; Wen Y; Xu J; Lu Y; Zhao D; Chen X; Li N
Eur J Pharm Sci; 2017 Jul; 105():219-229. PubMed ID: 28526602
[TBL] [Abstract][Full Text] [Related]
24. Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo.
Tardi PG; Dos Santos N; Harasym TO; Johnstone SA; Zisman N; Tsang AW; Bermudes DG; Mayer LD
Mol Cancer Ther; 2009 Aug; 8(8):2266-75. PubMed ID: 19671743
[TBL] [Abstract][Full Text] [Related]
25. Dual drug loaded liposome bearing apigenin and 5-Fluorouracil for synergistic therapeutic efficacy in colorectal cancer.
Sen K; Banerjee S; Mandal M
Colloids Surf B Biointerfaces; 2019 Aug; 180():9-22. PubMed ID: 31015105
[TBL] [Abstract][Full Text] [Related]
26. The influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma.
Alavizadeh SH; Badiee A; Golmohammadzadeh S; Jaafari MR
Int J Pharm; 2014 Oct; 473(1-2):326-33. PubMed ID: 25051111
[TBL] [Abstract][Full Text] [Related]
27. Folate receptor-mediated celastrol and irinotecan combination delivery using liposomes for effective chemotherapy.
Soe ZC; Thapa RK; Ou W; Gautam M; Nguyen HT; Jin SG; Ku SK; Oh KT; Choi HG; Yong CS; Kim JO
Colloids Surf B Biointerfaces; 2018 Oct; 170():718-728. PubMed ID: 30005409
[TBL] [Abstract][Full Text] [Related]
28. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo.
Tardi PG; Gallagher RC; Johnstone S; Harasym N; Webb M; Bally MB; Mayer LD
Biochim Biophys Acta; 2007 Mar; 1768(3):678-87. PubMed ID: 17208196
[TBL] [Abstract][Full Text] [Related]
29. A solvent-assisted active loading technology to prepare gambogic acid and all-trans retinoic acid co-encapsulated liposomes for synergistic anticancer therapy.
Na K; Liu K; Yu J; Wang X; Li M; Tian C; He H; He Y; Wang Y
Drug Deliv Transl Res; 2020 Feb; 10(1):146-158. PubMed ID: 31529371
[TBL] [Abstract][Full Text] [Related]
30. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
O'connor T; Rustum Y; Levine E; Creaven P
Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
[TBL] [Abstract][Full Text] [Related]
31. Synergistic antitumor activity of capecitabine in combination with irinotecan.
Cao S; Durrani FA; Rustum YM
Clin Colorectal Cancer; 2005 Jan; 4(5):336-43. PubMed ID: 15663838
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models.
Gabizon A; Amitay Y; Tzemach D; Gorin J; Shmeeda H; Zalipsky S
J Control Release; 2012 Jun; 160(2):245-53. PubMed ID: 22134116
[TBL] [Abstract][Full Text] [Related]
33. Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors.
Hattori Y; Shi L; Ding W; Koga K; Kawano K; Hakoshima M; Maitani Y
J Control Release; 2009 May; 136(1):30-7. PubMed ID: 19331859
[TBL] [Abstract][Full Text] [Related]
34. Enhanced therapeutic efficacy of a novel liposome-based formulation of SN-38 against human tumor models in SCID mice.
Lei S; Chien PY; Sheikh S; Zhang A; Ali S; Ahmad I
Anticancer Drugs; 2004 Sep; 15(8):773-8. PubMed ID: 15494639
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma.
Cheng Y; Zhao P; Wu S; Yang T; Chen Y; Zhang X; He C; Zheng C; Li K; Ma X; Xiang G
Int J Pharm; 2018 Jul; 545(1-2):261-273. PubMed ID: 29730175
[TBL] [Abstract][Full Text] [Related]
36. Liposomal prednisolone phosphate potentiates the antitumor activity of liposomal 5-fluorouracil in C26 murine colon carcinoma in vivo.
Patras L; Sylvester B; Luput L; Sesarman A; Licarete E; Porfire A; Muntean D; Drotar DM; Rusu AD; Nagy AL; Catoi C; Tomuta I; Vlase L; Banciu M; Achim M
Cancer Biol Ther; 2017 Aug; 18(8):616-626. PubMed ID: 28696813
[TBL] [Abstract][Full Text] [Related]
37. Dual functional octreotide-modified liposomal irinotecan leads to high therapeutic efficacy for medullary thyroid carcinoma xenografts.
Iwase Y; Maitani Y
Cancer Sci; 2012 Feb; 103(2):310-6. PubMed ID: 22017398
[TBL] [Abstract][Full Text] [Related]
38. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice.
Mayer LD; Harasym TO; Tardi PG; Harasym NL; Shew CR; Johnstone SA; Ramsay EC; Bally MB; Janoff AS
Mol Cancer Ther; 2006 Jul; 5(7):1854-63. PubMed ID: 16891472
[TBL] [Abstract][Full Text] [Related]
39. Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft models.
Matsuzaki T; Takagi A; Furuta T; Ueno S; Kurita A; Nohara G; Kodaira H; Sawada S; Hashimoto S
Oncol Rep; 2012 Jan; 27(1):189-97. PubMed ID: 21935577
[TBL] [Abstract][Full Text] [Related]
40. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.
Kalra AV; Kim J; Klinz SG; Paz N; Cain J; Drummond DC; Nielsen UB; Fitzgerald JB
Cancer Res; 2014 Dec; 74(23):7003-13. PubMed ID: 25273092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
